Medical - Vaccine Guide 2022 - 16

Notes
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022
Meningococcal serogroup A,C,W,Y vaccination
(minimum age: 2 months [MenACWY-CRM,
Menveo], 9 months [MenACWY-D, Menactra], 2 years
[MenACWY-TT, MenQuadfi])
Routine vaccination
y 2-dose series at age 11-12 years; 16 years
Catch-up vaccination
y Age 13-15 years: 1 dose now and booster at age 16-18 years
(minimum interval: 8 weeks)
y Age 16-18 years: 1 dose
Special situations
Anatomic or functional asplenia (including sickle cell disease),
HIV infection, persistent complement component deficiency,
complement inhibitor (e.g., eculizumab, ravulizumab) use:
y Menveo
- Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6
and 12 months)
- Dose 1 at age 3-6 months: 3- or 4- dose series (dose 2 [and dose
3 if applicable] at least 8 weeks after previous dose until a dose is
received at age 7 months or older, followed by an additional dose at
least 12 weeks later and after age 12 months)
- Dose 1 at age 7-23 months: 2-dose series (dose 2 at least 12 weeks
after dose 1 and after age 12 months)
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
y Menactra
- Persistent complement component deficiency or complement
inhibitor use:
 Age 9-23 months: 2-dose series at least 12 weeks apart
 Age 24 months or older: 2-dose series at least 8 weeks apart
- Anatomic or functional asplenia, sickle cell disease, or HIV
infection:
 Age 9-23 months: Not recommended
 Age 24 months or older: 2-dose series at least 8 weeks apart
 Menactra® must be administered at least 4 weeks after completion
of PCV13 series.
y MenQuadfi®
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
Travel in countries with hyperendemic or epidemic meningococcal
disease, including countries in the African meningitis belt or during
the Hajj (www.cdc.gov/travel/):
y Children less than age 24 months:
- Menveo® (age 2-23 months)
 Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6
and 12 months)
 Dose 1 at age 3-6 months: 3- or 4- dose series (dose 2 [and dose
3 if applicable] at least 8 weeks after previous dose until a dose is
received at age 7 months or older, followed by an additional dose at
least 12 weeks later and after age 12 months)
 Dose 1 at age 7-23 months: 2-dose series (dose 2 at least 12 weeks
after dose 1 and after age 12 months)
- Menactra® (age 9-23 months)
 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be
administered as early as 8 weeks after dose 1 in travelers)
y Children age 2 years or older: 1 dose Menveo®, Menactra®, or
MenQuadfi®
First-year college students who live in residential housing (if not
previously vaccinated at age 16 years or older) or military recruits:
y 1 dose Menveo®, Menactra®, or MenQuadfi®
henryschein.com/medical
16
Adolescent vaccination of children who received MenACWY prior to
age 10 years:
y Children for whom boosters are recommended because of an
ongoing increased risk of meningococcal disease (e.g., those with
complement deficiency, HIV, or asplenia): Follow the booster schedule
for persons at increased risk.
y Children for whom boosters are not recommended (e.g., a healthy
child who received a single dose for travel to a country where
meningococcal disease is endemic): Administer MenACWY according
to the recommended adolescent schedule with dose 1 at age 11-12
years and dose 2 at age 16 years.
Note: Menactra® should be administered either before or at the same
time as DTaP. MenACWY vaccines may be administered simultaneously
with MenB vaccines if indicated, but at a different anatomic site, if
feasible.
For MenACWY booster dose recommendations for groups listed
under " Special situations " and in an outbreak setting and additional
meningococcal vaccination information, see www.cdc.gov/mmwr/
volumes/69/rr/rr6909a1.htm.
Meningococcal serogroup B vaccination
(minimum age: 10 years [MenB-4C, Bexsero®;
MenB-FHbp, Trumenba®])
Shared clinical decision-making
y Adolescents not at increased risk age 16-23 years (preferred age
16-18 years) based on shared clinical decision-making:
- Bexsero®: 2-dose series at least 1 month apart
- Trumenba®: 2-dose series at least 6 months apart; if dose 2 is
administered earlier than 6 months, administer a 3rd
months after dose 2.
Special situations
Anatomic or functional asplenia (including sickle cell disease),
persistent complement component deficiency, complement
inhibitor (e.g., eculizumab, ravulizumab) use:
y Bexsero®: 2-dose series at least 1 month apart
y Trumenba®: 3-dose series at 0, 1-2, 6 months
Note: Bexsero® and Trumenba® are not interchangeable; the same
product should be used for all doses in a series.
For MenB booster dose recommendations for groups listed under
" Special situations " and in an outbreak setting and additional
meningococcal vaccination information, see www.cdc.gov/mmwr/
volumes/69/rr/rr6909a1.htm.
Pneumococcal vaccination
(minimum age: 6 weeks [PCV13], 2 years [PPSV23])
Routine vaccination with PCV13
y 4-dose series at age 2, 4, 6, 12-15 months
Catch-up vaccination with PCV13
y 1 dose for healthy children age 24-59 months with any incomplete*
PCV13 series
y For other catch-up guidance, see Table 2.
dose at least 4
Special situations
Underlying conditions below: When both PCV13 and PPSV23 are
indicated, administer PCV13 first. PCV13 and PPSV23 should not
be administered during same visit.
Chronic heart disease (particularly cyanotic congenital heart
disease and cardiac failure); chronic lung disease (including
asthma treated with high-dose, oral corticosteroids); diabetes
mellitus:
Age 2-5 years
y Any incomplete* series with:
- 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13
dose)
- Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most
recent dose and administered 8 weeks apart)
y No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing
all recommended PCV13 doses)
Age 6-18 years
y No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing
all recommended PCV13 doses)
Cerebrospinal fluid leak, cochlear implant:
Age 2-5 years
y Any incomplete* series with:
- 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13
dose)
- Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most
recent dose and administered 8 weeks apart)
y No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior
PCV13 dose)
Age 6-18 years
y No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at
least 8 weeks later
y Any PCV13 but no PPSV23: 1 dose PPSV23 at least 8 weeks after the
most recent dose of PCV13
y PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most
recent dose of PPSV23
Sickle cell disease and other hemoglobinopathies; anatomic or
functional asplenia; congenital or acquired immunodeficiency; HIV
infection; chronic renal failure; nephrotic syndrome; malignant
neoplasms, leukemias, lymphomas, Hodgkin disease, and other
diseases associated with treatment with immunosuppressive
drugs or radiation therapy; solid organ transplantation; multiple
myeloma:
Age 2-5 years
y Any incomplete* series with:
- 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13
dose)
- Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most
recent dose and administered 8 weeks apart)
y No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior
PCV13 dose) and a dose 2 of PPSV23 5 years later
Age 6-18 years
y No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23
(dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of
PPSV23 administered at least 5 years after dose 1 of PPSV23)
y Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23
administered 8 weeks after the most recent dose of PCV13 and dose 2
of PPSV23 administered at least 5 years after dose 1 of PPSV23)
y PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most
recent PPSV23 dose and a dose 2 of PPSV23 administered 5 years after
dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13
22MS6015
http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm http://www.cdc.gov/travel/ http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm http://www.henryschein.com/medical
Medical - Vaccine Guide 2022

Table of Contents for the Digital Edition of Medical - Vaccine Guide 2022
